HAIKOU,
China, Nov. 29, 2023 /PRNewswire/ --
China Pharma Holdings, Inc. (NYSE American: CPHI)
("China Pharma", or the "Company"), an NYSE American-listed
corporation with a fully-integrated specialty pharmaceuticals
subsidiary based in China, today
announced that its Dry Eye Disease (DED) therapeutic device has
passed third-party testing and is preparing to apply for market
launch to the National Medical Products Administration (NMPA) of
China.
According to a disclosure by the Shanghai Public Health Clinical
Center on June 6, 2023, an
epidemiological survey of DED showed that approximately 344 million
patients are suffering from DED worldwide, accounting for 30% of
the total number of ophthalmic outpatient visits, with an annual
increase of 10%. There are about 80 million DED patients in
China, ranking second in
ophthalmic diseases.
- This device has a utility model patent;
- Epidemiological research shows that the incidence rate
of DED for all the people in China is about 25% to 30%, and about 75% for
people over 65-year-old;
- In the field of DED and visual fatigue, this product
is expected to fill in the market gap of medical therapeutic
apparatus; and
- The Company has established sales channels in more than 30
provincial and municipal hospitals, as well as OTC markets in
China for more than 20 years. This
sales network may strongly support the launch and promotion of this
device.
Ms. Li Zhilin, CEO of China
Pharma said: " After passing third-party testing, this product has
obtained qualifications to apply for market approval from NMPA. We
are actively working to try to launch this product in the first
half of next year. We are confident that with the patented
technological advantages and our sales channels, the launch of this
product will bring excellent treatment experience to every DED
patient, which will create value for our shareholders."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical
company that develops, manufactures and markets a diversified
portfolio of products, focusing on conditions with high incidence
and high mortality rates in China,
including cardiovascular, CNS, infectious, and digestive diseases.
The Company's cost-effective business model is driven by market
demand and supported by new GMP-certified product lines covering
the major dosage forms. In addition, the Company has a broad and
expanding nationwide distribution network across all major cities
and provinces in China. The
Company's wholly-owned subsidiary, Hainan Helpson Medical &
Biotechnology Co., Ltd., is located in Haikou City, Hainan
Province. For more information about China Pharma Holdings,
Inc., please visit www.chinapharmaholdings.com. The Company
routinely posts important information on its website.
Safe Harbor Statement
Certain statements in this press release constitute
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Any statements set forth above that are not historical facts
are forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements. Such risks and uncertainties may
include, but are not limited to: the achievability of financial
guidance; success of new product development; unanticipated changes
in product demand; increased competition; downturns in the Chinese
economy; uncompetitive levels of research and development; and
other information detailed from time to time in the Company's
filings and future filings with the United States Securities and
Exchange Commission. The forward-looking statements made herein
speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to
conform the statement to actual results or changes in the Company's
expectations, except as required by applicable law or
regulation.
View original
content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announced-the-completion-of--third-party-testing-of-dry-eye-disease-therapeutic-device-302000153.html
SOURCE China Pharma Holdings, Inc.